Paul Sekhri joined Compugen’s Board of Directors in 2017. Mr. Sekhri has over 25 year of experience in the life sciences industry. He currently serves as President and CEO of Lycera Corp. Prior to joining Lycera, Mr. Sekhri served in senior management positions at Sanofi, Teva Pharmaceutical Industries, ARIAD Pharmaceuticals, Cerimon Pharmaceuticals, Inc and Novartis. Mr. Sekhri also served as Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, the life sciences venture capital arm of TPG Capital. Mr. Sekhri has been a director on more than 20 private and public company boards, and is currently a member of the Board of Directors of Veeva Systems Inc. and Alpine Immune Sciences, Inc.; Mr. Sekhri is also the Chairman of the Board of Pharming N.V., Petra Pharma, and Topas Therapeutics GmbH. Additionally, he serves on several non-profit boards including the BioExec Institute, Inc., the TB Alliance, Young Concert Artists, Inc., The English Concert in America (TECA), and the Caramoor Center for Music and the Arts. Mr. Sekhri also served as a Member of the Board of Trustees of Carnegie Hall from 2010-2012, where he is now an active member of their Patrons Council. Mr. Sekhri completed graduate work in Neuroscience at the University of Maryland School of Medicine, where he also received his BS in Zoology.
Dr. Anat Cohen-Dayag joined Compugen’s Board of Directors in 2014. Dr. Cohen-Dayag joined Compugen in 2002 and held various positions. In November 2008, Dr. Cohen-Dayag was appointed as Vice President, Research and Development. In June 2009, Dr. Cohen-Dayag was appointed, together with Mr. Martin Gerstel, as co-Chief Executive Officer of Compugen. In March 2010, upon Mr. Gerstel’s election as Chairman of the Board of Directors, Dr. Cohen-Dayag was appointed as Compugen’s President and CEO. Prior to joining Compugen, Dr. Cohen-Dayag was head of research and development and member of the Executive Management at Mindsense Biosystems Ltd. Prior to Mindsense Biosystems Ltd., Dr. Cohen-Dayag served as a scientist at the R&D department of Orgenics Ltd. Dr. Cohen-Dayag holds a B.Sc. in Biology from the Ben-Gurion University, Israel, and an M.Sc. in Chemical Immunology and a Ph.D. in Cellular Biology, both from the Weizmann Institute of Science, Israel. Additionally, Dr. Cohen-Dayag is a director of Ramot at Tel-Aviv University Ltd., and a director of the IATI (Israeli Advanced Technologies Industries).
Prof. Aharonowitz joined Compugen’s Board of Directors as an external director in 2007 and was reappointed as an external director in 2010 and 2013. He is a Professor Emeritus of Microbiology and Biotechnology, George S. Wise Faculty of Life Sciences at Tel Aviv University (TAU). He was a visiting scientist at Oxford University, an Alberta Heritage Fellow at the University of Alberta, Edmonton, and a visiting professor at the Karolinska Institute and at the University of British Columbia. Professor Aharonowitz’s research interests include the molecular genetics and biosynthesis of antibiotics, molecular biology of microbial pathogens and the development of new targets for new antibiotics. He served as TAU Vice President and Dean for R&D (1997-2001), Chairman of the Department of Microbiology and Biotechnology and Chairman of the Institute of Biotechnology and served as a member of the TAU Executive Council. He served as the Chairman of Ramot Fund for Applied Research, as a member of TAU committee for strategic planning, on the TAU patent committee and was a member of the National Committee for Biotechnology. He is a Fellow of the American Academy of Microbiology.
Prof. Arnon joined Compugen’s Board of Directors in 2007. Formerly the Vice-President of the Weizmann Institute of Science (1988-1997), she is a noted immunologist, having joined the Institute in 1960. She served as Head of the Department of Chemical Immunology, Dean of the Faculty of Biology and Director of the Institute's MacArthur Center for Molecular Biology of Tropical Diseases. Prof. Arnon has made significant contributions to the fields of vaccine development, cancer research and the study of parasitic diseases. Along with Prof. Michael Sela, she developed Copaxone® a drug for the treatment of multiple sclerosis which is presently marketed worldwide. Prof. Arnon is a member of the Israel Academy of Sciences and presently serves as its President. She is an elected member of the European Molecular Biology Organization, served as President of the European Federation of Immunological Societies and as Secretary-General of the International Union of Immunological Societies. Her awards include the Robert Koch Prize in Medical Sciences, Spain's Jiminez Diaz Memorial Prize, France's Legion of Honor, the Hadassah World Organization's Women of Distinction Award, the Wolf Prize for Medicine, the Rothschild Prize for Biology, the Israel Prize and an Honorary Doctorate from Ben-Gurion University and from Tel Aviv University. In addition, Prof. Arnon is the incumbent of the Paul Ehrlich Chair in Immunochemistry at the Weizmann Institute.
Gilead Halevy joined Compugen’s Board of Directors in 2018. Mr. Halevy brings to Compugen extensive experience in complex cross-border transactions, deal making and finance. He is a founding member and general partner of Kedma Capital Partners, a leading Israeli private equity fund since 2006. Prior to establishing Kedma, from 2001 to 2006, Mr. Halevy was with Giza Venture Capital, where he led investments in communication and information technology companies, and directed Giza’s European business activities. Previously, from 1998 to 2001, Mr. Halevy practiced law at White & Case LLP., where he was also a founding member of the firm’s Israel practice. Mr. Halevy currently serves as chairman of Brand Industries Ltd., Carmor Integrated Solutions Ltd., Carmel Wineries, Continuity Software Ltd. And S.AL Holdings. Mr. Halevy holds a B.A. in Humanities (multidisciplinary program for exceptional students) and an LL.B. (Magna Cum Laude) both from the Hebrew University of Jerusalem.
Dr. Kinneret Livnat Savitzky joined Compugen’s Board of Directors in 2018. Dr. Livnat Savitzky brings to Compugen significant experience in the life sciences industry, including drug discovery and development, corporate partnering and capital raising. She currently serves as the Interim CEO and a board member of FutuRx Ltd., an Israeli biotechnology accelerator established by OrbiMed Israel Partners, Johnson & Johnson Innovation and Takeda Ventures Inc. (the venture group of Takeda Pharmaceutical Company). Dr. Livnat Savitzky also serves on the boards of the following biotechnology or healthcare companies: as an active chairperson in KAHR Medical and ImmPACT-Bio, and as a director in Evogene Ltd. Hadasit, and DreaMed Diabetes. In addition, Dr. Livnat Savitzky serves as a consultant to other pharmaceutical development companies and related funds. From 2010 to 2016, Dr. Livnat Savitzky served as CEO of NASDAQ-listed BioLineRx Ltd. Prior to being appointed CEO of BioLineRx, Dr. Livnat Savitzky held various R&D management positions at BioLineRx and Compugen. Dr. Livnat Savitzky holds a B.Sc. in Biology from The Hebrew University of Jerusalem, and an M.Sc. and Ph.D. with distinction in Human Genetics from Tel Aviv University.
Dr. Ovadia joined Compugen’s Board of Directors as an external director in 2007 and was reappointed as an external director in 2010 and 2013. He advises major Israeli companies on finance, accounting and valuations, and is a member of the Board of Directors of several corporations, including Strauss Ltd., Israel Petrochemical Industries Ltd., Bazan Ltd., Maxtech Technologies Ltd., and Elron Electronic Industries Ltd. He has taught at New York University, Temple University and, in Israel, at Tel Aviv and Bradford Universities and at the College of Management. Dr. Ovadia served as a member of the Israeli Accounting Board, and is a 14-year member of the Israel Securities Authority. Dr. Ovadia holds an undergraduate degree and an MBA from Tel Aviv University, and earned his Ph.D. in economics from the Wharton School at the University of Pennsylvania.
Dr. Preminger joined Compugen’s Board of Directors in 2017. Dr. Preminger is the Executive Director at Harvard University’s Office of Technology Development's Harvard Medical School site, overseeing industry partnerships, startup formation and development of scientific programs and discoveries emerging from research at Harvard Medical School. In this role, she has initiated and negotiated a multitude of licensing and strategic alliance agreements with pharmaceutical and biotechnology companies and supported the launch of many biotechnology startups. Prior to joining Harvard in 2005, Dr. Preminger held a number of senior executive business development and R&D positions in technology and biotechnology companies, including at Compugen, where she was a member of the management team that took the Company public in August 2000. In addition, she is currently a member of the Board of Directors at BioArray Genetics and Israel Brain Technologies, and a member of the Scientific Advisory Board at Futurx Accelerator (Takeda/J&J/Orbimed) and Prize for Life. Dr. Preminger holds an undergraduate degree in Medicine from the Hebrew University of Jerusalem’s School of Medicine, MSc and PhD from the Weizmann Institute of Science, and an MBA from INSEAD in Fontainebleau, France.
Sanford Zweifach joined Compugen’s Board of Directors in 2018. Mr. Zweifach is senior executive with over 25 years’ experience in the life sciences industry. He has an extensive background in corporate partnering, business development, operations, private and public investing, and capital raising. Mr. Zweifach is the Founder and Chief Executive Officer of Nuvelution Pharma, Inc. since 2015. Previously, from 2010 to 2015, Mr. Zweifach served as CEO of Ascendancy Healthcare, Inc., which he also founded. He has also been a Partner at Reedland Capital Partners, a boutique investment bank, from 2005 to 2010, where he headed its life sciences M&A and advisory efforts. Prior to this, he was CEO of Pathways Diagnostics, a biomarker development company. Mr. Zweifach was a Managing Director/CFO of Bay City Capital, a venture capital/merchant banking firm, specializing in the biotech and the life science industry, where he was President of the firm’s M&A and financing division and was also responsible for oversight of the firm’s finance department. Prior to this, he was President and CFO of Epoch Biosciences, which was acquired by Nanogen in 2004. Currently, he is Chairman of Lyric Pharmaceuticals Inc., Chairman of IMIDomics, S.L., and a Director of Realm Therapeutics, Inc. Earlier in his career, Mr. Zweifach was a Certified Public Accountant (US) for Coopers & Lybrand and held various investment banking positions focusing on biotech. He received his B.A. in Biology from UC San Diego and an M.S. in Human Physiology from UC Davis.